Wolfe Research initiated coverage of Stevanato Group (STVN) with an Outperform rating and $28 price target The company is poised to return to double-digit revenue growth as a supplier of key enabling components and solutions to biopharma, the analyst tells investors in a research note. The firm does not expect Stevanato’s growth to inflect, but believes it “is on the verge of turning the corner.” The company’s revenue growth should return to high-single digit levels over the course of 2025 and margins will improve via growth and mix, contends Wolfe.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STVN: